Complement Screening Using Cytotoxicity Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for screening therapeutic drugs for diseases involving excessive complement activation do not adequately consider cytotoxicity such as vascular injury, which can occur due to complement activation, and lack reliable indicators for evaluating cytotoxicity.
Innovation Solution
A method using cytotoxicity markers associated with complement activation, involving the induction of cytotoxicity in cells derived from stem cells, and the evaluation of therapeutic drug candidates that decrease these markers, along with a kit comprising cells, complement sources, and reagents for detecting cytotoxicity markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hemolytic action-based screening methods are used, then complement activation can be detected, but cytotoxicity such as vascular injury cannot be adequately evaluated
Solution Approach 1:
The patent changes the measurement parameter from hemolytic action (conventional method) to cytotoxicity markers including vascular injury markers, enabling comprehensive evaluation of complement activation effects. This parameter change allows detection of both hemolytic action and vascular cytotoxicity, resolving the contradiction between screening capability and cytotoxicity evaluation precision.
Solution Approach 2:
The patent introduces cytotoxicity markers as intermediary indicators that mediate between complement activation and observable damage. These markers serve as intermediaries to detect vascular injury and cellular cytotoxicity that conventional hemolytic assays cannot measure, thereby improving both screening reliability and cytotoxicity evaluation precision simultaneously.
2Object-affected harmful factors
If heat-treated complement is used, then cytotoxicity is reduced, but the ability to screen for therapeutic agents against active complement activation is diminished
Solution Approach 1:
The patent uses heat-treated complement in a controlled partial manner - treating it to reduce cytotoxicity for safety while preserving enough complement structure to maintain screening capability. This partial action allows the system to function both as a safe test substrate and as an effective screening tool for therapeutic agents.
Solution Approach 2:
The patent employs heat-treated complement as a disposable, controlled substrate that can be prepared in advance, stored, and used for multiple screening experiments. This approach eliminates the need for fresh active complement preparations while maintaining screening reliability through standardized, reproducible heat-treated samples.
3Measurement precision
If multiple cytotoxicity markers are measured, then comprehensive cytotoxicity evaluation is achieved, but measurement complexity and time increase
Solution Approach 1:
The patent merges multiple cytotoxicity marker measurements into a unified screening assay system. By combining detection of different cytotoxicity markers (including vascular injury markers and cellular cytotoxicity markers) into a single integrated protocol, the method achieves comprehensive evaluation without requiring separate experiments for each marker, thereby reducing total screening time.
Solution Approach 2:
The patent develops a universal screening method that can detect multiple types of cytotoxicity through a single assay system. This multi-functional approach allows simultaneous evaluation of hemolytic action, vascular injury, and cellular cytotoxicity using the same basic protocol and reagents, eliminating the need for multiple specialized assays and significantly reducing screening time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for more reliable screening of therapeutic drugs by assessing the reduction of cytotoxicity markers, reflecting the actual in vivo effects of complement activation on blood vessel injury, thereby improving the drug discovery process.
Implementation Method 1
activation of complement forms a so membrane attack complex (MAC), and the formation of MAC creates structural pores in the cell membrane
Implementation Method 2
movement of osmotic pressure fluid and influx of cation occur, which in turn causes cell death
Implementation Method 3
NHS heat-treated to inactivate complement
Data Source
AI summary
A method for screening for a therapeutic drug for a disease involving excessive activation of a complement, using a s cytotoxicity marker associated with the complement as an index, including (1a) a step of adding a complement to a cell produced from a stem cell to cause the cell to form a cytotoxicity marker associated with the complement, and (2a) a step of adding a therapeutic drug candidate, and selecting a substance that decreases the amount of the cytotoxicity marker is provided by the present invention.